EACS - 14th European AIDS Conference EACS - European AIDS Conference Oct 12-15 2011 Belgrade, Serbiay

Conference Reports for NATAP


EACS - 14th European AIDS Conference European AIDS Conference Oct 12-15 2011 Belgrade, Serbiay

	Pharmacokinetics, efficacy and safety of switching from efavirenz to maraviroc twice-daily in patients suppressed on an efavirenz-containing regimen as initial therapy (11/02/11) Predictors of Hepatitis C RNA Levels in HIV Co-infected Individuals in a Prospective Cohort Study (10/25/11) High non-AIDS-related mortality among a cohort of HIV-positive men who have sex with men (MSM) in Stockholm Insulin resistance is a strong predictor of mortality- a 12 year follow (10/23/11) Predictors of Hepatitis C RNA Levels in HIV Co-infected Individuals in a Prospective Cohort Study (10/23/11) Factors influencing neurocognitive function in a large cohort of HIV infected patients on effective antiretroviral therapy (10/20/11) Rilpivirine vs Efavirenz for 96 Weeks: Baseline Viral Load and Side Effect Details - Written by Mark Mascolini (10/19/11) IL28B gene polymorphisms and all-cause mortality in HIV infected patients (10/19/11) IL28B Genotype Linked to All-Cause Mortality in HIV+ People on cART - written by Mark Mascolini - (10/18/11) Half With Undetectable Plasma Load Have Neurocognitive Impairment in UK Group - written by Mark Mascolini - (10/18/11) Dolutegravir (GSK/ViiV Integrase) Treatment (with 50mg Once & Twice Daily) of HIV Subjects with Raltegravir Resistance & 3-Class ART Resistance: viral suppression at Week 24 in the VIKING Study (10/17/11) Switching from Efavirenz/Emtricitabine/Tenofovir DisoproxilFumarate(EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir DisoproxilFumarate(FTC/RPV/TDF) STR in VirologicallySuppressed, HIV-1 Infected Subjects (10/17/11) Sustained Efficacy with Low and Similar Rates of Virologic Failures in Second Year Observed with Rilpivirine (RPV) versus Efavirenz (EFV) plus Emtricitabine/Tenofovir DF (FTC/TDF) in Treatment-Naïve, HIV-1 Infected Adults - Pooled 96-Week ECHO and THRIVE Analysis (10/17/11) Non-AIDS Cancer Incidence Remains the Same Over 2004-2010 in D:A:D Study Group - written by Mark Mascolini - (10/17/11) Half of HIV+ in France Still Coming to Care Late--With High Death Risk - written by Mark Mascolini - (10/17/11) Body Fat Distribution Changes After 96 Weeks of Therapy with Lopinavir/ritonavir (LPV/r) Plus Raltegravir (RAL) Compared with LPV/r Plus Tenofovir/Emtricitabine (TDF/FTC) in Antiretroviral (ARV)-Naïve, HIV-1-Infected Subjects from the PROGRESS Study (10/17/11) Efficacy and viral resistance are comparable when maraviroc is administered once daily or twice daily with boosted protease inhibitors in treatment-experienced patients (10/17/11) Pilot study evaluating an intensification of antiretroviral therapy with maraviroc in HIV-1-infected patients with controlled viral load exhibiting insufficient immune restoration (10/17/11) The incidence of serious non-AIDS bacterial infections in the EuroSIDA cohort (10/17/11) Interleukin-6 and C-reactive Protein Levels after 144 Weeks of Efficacy of Darunavir /Ritonavir Monotherapy versus DRV/r + 2NRTIs in the MONET Trial for Patients with HIV RNA < 50 Copies/mL at Baseline: COINFECTED PATIENTS HAD HIGHER IL-6, INFLAMMATION LEVELS (In SMART >3 mg/L was associated with progression), YOU CAN SEE 15% to 19% of PATIENTS HAD VERY HIGH hs-CRP (inflammation) (>3 mg/L), INFLAMMATION WAS MORE LIKELY TO BE HIGHER IF VIRAL LOAD WAS DETECTABLE (10/17/11) Long-term Efficacy of Raltegravir or Efavirenz Combined with TDF/FTC in Treatment-naïve HIV-1-infected Patients: Week-192 Subgroup Analyses from STARTMRK (10/14/11)